Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Joseph

Showing results (521-530 of 531) with videos related to

Pageof 54
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 29, 2019
Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestorsSean C Patro, Leah D Brandt, Michael J Bale, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Alain Algazi, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Plos One|April 7, 2021
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trialPatricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, et al.
JCO Precision Oncology|February 15, 2019
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in CholangiocarcinomaJan B Egan, David L Marks, Tara L Hogenson, et al.
Pageof 54

Showing results (521-530 of 531) with videos related to

Sort By:
Pageof 54
Proceedings of the National Academy of Sciences of the United States of America|November 29, 2019
Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestorsSean C Patro, Leah D Brandt, Michael J Bale, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Alain Algazi, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Plos One|April 7, 2021
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trialPatricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, et al.
JCO Precision Oncology|February 15, 2019
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in CholangiocarcinomaJan B Egan, David L Marks, Tara L Hogenson, et al.
Pageof 54